Federica Mossa

Jan 14, 2025 | genomemedicine.biomedcentral.com | Bethany Hughes |Andrew Davis |Deborah Milligan |Ryan Wallis |Federica Mossa |Michael Philpott | +3 more

ReferencesHernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol. 2018;28:436–53. Article  PubMed  Google Scholar  González-Gualda E, Baker AG, Fruk L, Muñoz-Espín D. A guide to assessing cellular senescence in vitro and in vivo. FEBS J. 2021;288:56–80. Article  PubMed  Google Scholar  Huang W, Hickson LJ, Eirin A, Kirkland JL, Lerman LO. Cellular senescence: the good, the bad and the unknown. Nat Rev Nephrol. 2022;18:611–27.

Sep 13, 2024 | nature.com | Ryan Wallis |Federica Mossa

AbstractSenescence is an anti-tumour mechanism and hallmark of cancer. Loss or mutation of key senescence effectors, such as p16INK4A, are frequently observed in cancer. Intriguingly, some human tumours are both proliferative and senescent-marker positive (Sen-Mark+). Here, we explore this paradox, focusing on the prognostic consequences and the current challenges in classifying these cells.